Polarean Imaging plc (AIM: POLX) (“Polarean” or the “Company”), a
commercial-stage leader in advanced medical imaging focused on
functional Magnetic Resonance Imaging ("MRI") of the lungs,
announces a strategic collaboration with SimonMed Imaging, one of
the largest outpatient medical imaging providers in the United
States, to expand access to Polarean’s cutting-edge Xenon MRI
platform.
SimonMed Imaging operates in over 170 facilities
across 11 states, offering comprehensive medical imaging with
cutting-edge technology and artificial intelligence, all with an
emphasis on affordability and accessibility. This collaboration
will integrate Polarean’s innovative Xenon MRI platform within
SimonMed’s network, enhancing diagnostic capabilities and advancing
the standard of care for patients with pulmonary diseases.
The first SimonMed site to adopt Polarean’s
Xenon MRI platform will be in Scottsdale, Arizona, which is
expected to be installed later this year, with scope to increase
the number of sites installing systems as the collaboration
matures.
The integration of Polarean’s Xenon MRI platform
into SimonMed’s facilities represents a new business opportunity to
expand the availability of functional lung imaging. This
collaboration underscores both organizations’ dedication to
advancing medical technologies that enhance patient care and
improve clinical outcomes.
Dr. John Simon, Founder and CEO of
SimonMed Imaging, stated: “At SimonMed, our mission is to
bring the newest diagnostic imaging technologies to the community
in a way that is both accessible and affordable. Polarean’s
groundbreaking work with Xenon MRI aligns perfectly with our
mantra, ‘See Tomorrow Today’. This technology provides an
unparalleled ability to visualize lung function, offering critical
insights for patients with respiratory conditions such as asthma,
COPD, and unexplained dyspnea. Together, we are committed to
delivering innovative solutions that have the potential to improve
diagnostic accuracy and patient outcomes.”
Christopher von Jako, Ph.D., CEO of
Polarean, added: “SimonMed’s dedication to making imaging
technologies widely accessible mirrors Polarean’s vision of
optimizing lung health and illuminating hidden disease, making
SimonMed an ideal collaboration partner. Together, we aim to bring
a much-needed imaging tool to clinicians, enabling them to see lung
function with unprecedented clarity and precision to help them
manage their patients’ disease. We look forward to establishing a
strong program in Scottsdale to serve as a model for potential
expansion to several additional SimonMed’s sites.”
About Polarean
Polarean is a revenue-generating medical imaging
technology company revolutionizing pulmonary medicine through
direct visualization of lung function by introducing the power and
safety of MRI to the respiratory healthcare community. This
community is in desperate need of modern solutions to accurately
assess lung function. The Company strives to optimize lung health
and prevent avoidable loss by illuminating hidden disease,
addressing the global unmet medical needs of more than 500 million
patients worldwide suffering from chronic respiratory disease.
Polarean is a leader in the field of hyperpolarization science and
has successfully developed the first and only hyperpolarized Xenon
MRI inhaled contrast agent, XENOVIEW™, which is now FDA-approved in
the United States. Polarean is dedicated to researching,
developing, and commercializing innovative imaging solutions with
its non-invasive and radiation-free pulmonary functional MRI
platform. This comprehensive drug-device platform encompasses the
proprietary Xenon gas blend, gas hyperpolarization system, as well
as software and accessories, facilitating fully integrated modern
respiratory imaging operations. Founded in 2012, with offices in
Durham, NC, and London, United Kingdom, Polarean is committed to
increasing global awareness of and broad access to its XENOVIEW MRI
technology platform. For the latest news and information about
Polarean, please visit www.polarean.com.
About SimonMed
Headquartered in Scottsdale, Arizona, SimonMed
is one of the largest outpatient medical imaging providers and
radiology practices in the United States. SimonMed has
approximately 170 sites across 11 states and over 200
subspecialty-trained radiologists. SimonMed offers the full modality
of diagnostic scans, including 3T MRI, CT, ultrasound, 3-D
mammography, PET/CT, nuclear medicine, DEXA, X-rays, among others.
The company uses the newest, most advanced, diagnostic imaging
technologies while maintaining affordability and accessibility.
SimonMed is a worldwide leader in the clinical use of AI to improve
diagnoses with one of the largest global deployments to enhance
early breast cancer detection and in the evaluation of brain
disorders. For more information, please visit www.SimonMed.com
XENOVIEW IMPORTANT SAFETY
INFORMATION
IndicationXENOVIEW™, prepared
from the Xenon Xe 129 Gas Blend, is a hyperpolarized contrast agent
indicated for use with magnetic resonance imaging (MRI) for
evaluation of lung ventilation in adults and pediatric patients
aged 12 years and older.
Limitations of UseXENOVIEW has
not been evaluated for use with lung perfusion imaging.
CONTRAINDICATIONSNone.
Warnings and PrecautionsRisk of
Decreased Image Quality from Supplemental Oxygen: Supplemental
oxygen administered simultaneously with XENOVIEW inhalation can
cause degradation of image quality. For patients on supplemental
oxygen, withhold oxygen inhalation for two breaths prior to
XENOVIEW inhalation, and resume oxygen inhalation immediately
following the imaging breath hold.
Risk of Transient Hypoxia: Inhalation of an
anoxic gas such as XENOVIEW may cause transient hypoxemia in
susceptible patients. Monitor all patients for oxygen desaturation
and symptoms of hypoxemia and treat as clinically indicated.
Adverse Reactions Adverse
Reactions in Adult Patients: The adverse reactions (> one
patient) in efficacy trials were oropharyngeal pain, headache, and
dizziness. Adverse Reactions in Pediatric and Adolescent
Patients: In published literature in pediatric patients aged 6 to
18, transient adverse reactions were reported: blood oxygen
desaturation, heart rate elevation, numbness, tingling, dizziness,
and euphoria. In at least one published study of pediatric patients
aged 6 to 18 years, transient decrease in SpO2% and transient
increase in heart rate was reported following hyperpolarized xenon
Xe 129 administration. XENOVIEW is not approved for use in
pediatric patients less than 12 years of age.
Please see full prescribing information at
www.xenoview.net.
Contact Information:Polarean: Chuck Osborne
Chief Financial Officer +1 (919) 206-7900, ext. 117
cosborne@polarean.com Polarean Investors: Anna Dunphy /
Phillip Marriage +44 (0)20 7933 8780
polarean@wallbrookpr.comPolarean Media Contact: Alexis Opp +1 (919)
206-7900, ext. 145 aopp@polarean.com SimonMed PR
Contact:Michelle Kafkamichelle.kafka@kafkamediagroup.com
General inquiries: info@polarean.com Follow Polarean on
LinkedIn here
- Polarean and SimonMed Announce Collaboration
Polarean:
Chuck Osborne
Chief Financial Officer
+1 (919) 206-7900, ext. 117
cosborne@polarean.com
Polarean Investors:
Anna Dunphy / Phillip Marriage
+44 (0)20 7933 8780
polarean@wallbrookpr.com
Polarean Media Contact:
Alexis Opp
+1 (919) 206-7900, ext. 145
aopp@polarean.com
SimonMed PR Contact:
Michelle Kafka
michelle.kafka@kafkamediagroup.com
General inquiries: info@polarean.com
Polarean Imaging (LSE:POLX)
過去 株価チャート
から 1 2025 まで 2 2025
Polarean Imaging (LSE:POLX)
過去 株価チャート
から 2 2024 まで 2 2025